International Journal of Clinical Oncology

, Volume 19, Issue 2, pp 247–253

Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil

  • Sung Hak Lee
  • Eun Ji Choi
  • Min Sik Kim
  • Jun Wook Park
  • Youn Soo Lee
  • Su Young Kim
  • Chang Suk Kang
Original Article

Abstract

Background

Syndecan-1 (SDC1) is reported to modulate several key processes of tumorigenesis and to show variable expression in many cancers. The cause of these variations in expression is not known to date. In this study, we compared SDC1 status with clinicopathologic parameters to evaluate the prognostic implications of SDC1 status on squamous cell carcinoma (SCC) of the tonsil.

Methods

In 56 cases of tonsillar SCC, we screened SDC1 expression using immunohistochemistry and analyzed the relationships between SDC1 expression and clinicopathological parameters. To identify the cause of the changes in SDC1 expression seen in tumors, we measured the gene dosage of SDC1 in tumor cells using fluorescent in situ hybridization.

Results

SDC1 expression was found in cancer cells in 36 cases (64.3 %) of tonsillar SCC. It was associated with lymph node metastasis (p = 0.010) and a positive surgical resection margin (p = 0.014). On the other hand, it was not significantly correlated with sex, age, smoking status, degree of differentiation, T stage, or distant metastasis. We could not find any copy-number variation of SDC1 in the cases showing increased SDC1 immunopositivity. In addition, strong SDC1 expression in the tumor cells predicted a shorter overall survival (p = 0.020, log-rank).

Conclusions

We showed that SDC1 expression is associated with N stage and the status of resection margin involvement in SCC of the tonsil. With respect to survival, there were unfavorable outcomes in cases with SDC1 positivity. More studies are needed to better understand the role of SDC1 in the progression and invasiveness of tonsillar SCC.

Keywords

Tonsil Squamous cell carcinoma Syndecan-1 Expression Prognosis 

References

  1. 1.
    Teng YH, Aquino RS, Park PW (2012) Molecular functions of syndecan-1 in disease. Matrix Biol 31:3–16PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Rapraeger AC (2001) Molecular interactions of syndecans during development. Semin Cell Dev Biol 12:107–116PubMedCrossRefGoogle Scholar
  3. 3.
    Bernfield M, Gotte M, Park PW et al (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729–777PubMedCrossRefGoogle Scholar
  4. 4.
    Anttonen A, Kajanti M, Heikkila P et al (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 79:558–564PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Al-Shibli K, Al-Saad S, Andersen S et al (2010) The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 118:371–382PubMedCrossRefGoogle Scholar
  6. 6.
    Anttonen A, Heikkila P, Kajanti M et al (2001) High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32:297–305PubMedCrossRefGoogle Scholar
  7. 7.
    Kim YI, Lee A, Lee BH et al (2011) Prognostic significance of syndecan-1 expression in cervical cancers. J Gynecol Oncol 22:161–167PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Shimada K, Nakamura M, De Velasco MA et al (2010) Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci 101:155–160PubMedCrossRefGoogle Scholar
  9. 9.
    Rasmussen T, Lodahl M, Hancke S et al (2004) In multiple myeloma clonotypic CD38-/CD19+/CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma 45:1413–1417PubMedCrossRefGoogle Scholar
  10. 10.
    Huff CA, Matsui W (2008) Multiple myeloma cancer stem cells. J Clin Oncol 26:2895–2900PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Alexander CM, Reichsman F, Hinkes MT et al (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25:329–332PubMedCrossRefGoogle Scholar
  12. 12.
    Joensuu H, Anttonen A, Eriksson M et al (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62:5210–5217PubMedGoogle Scholar
  13. 13.
    Seidel C, Sundan A, Hjorth M et al (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388–392PubMedGoogle Scholar
  14. 14.
    Roh YH, Kim YH, Choi HJ et al (2008) Syndecan-1 expression in gallbladder cancer and its prognostic significance. Eur Surg Res 41:245–250PubMedCrossRefGoogle Scholar
  15. 15.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  16. 16.
    Moon SH, Choi JY, Lee HJ et al (2012) Prognostic value of (18) F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck 35(1):15–22PubMedCrossRefGoogle Scholar
  17. 17.
    Lee SY, Park SY, Kim SH et al (2011) Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol 4:88–94PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    St Guily JL, Clavel C, Okais C et al (2011) Human papillomavirus genotype distribution in tonsil cancers. Head Neck Oncol 3:6PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Patel SG, Shah JP (2005) TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 55:242–58; quiz 261–262, 264Google Scholar
  21. 21.
    Poulsen M, Porceddu SV, Kingsley PA et al (2007) Locally advanced tonsillar squamous cell carcinoma: treatment approach revisited. Laryngoscope 117:45–50PubMedCrossRefGoogle Scholar
  22. 22.
    Lindquist D, Romanitan M, Hammarstedt L et al (2007) Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1:350–355PubMedCrossRefGoogle Scholar
  23. 23.
    Mennerich D, Vogel A, Klaman I et al (2004) Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 40:1373–1382PubMedCrossRefGoogle Scholar
  24. 24.
    Mukunyadzi P, Liu K, Hanna EY et al (2003) Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 16:796–801PubMedCrossRefGoogle Scholar
  25. 25.
    Hammarstedt L, Dahlstrand H, Lindquist D et al (2007) The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 127:988–992PubMedCrossRefGoogle Scholar
  26. 26.
    Hammarstedt L, Lindquist D, Dahlstrand H et al (2006) Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119:2620–2623PubMedCrossRefGoogle Scholar
  27. 27.
    Inki P, Joensuu H, Grenman R et al (1994) Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer 70:319–323PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Ramani VC, Pruett PS, Thompson CA et al (2012) Heparan sulfate chains of syndecan-1 regulate ectodomain shedding. J Biol Chem 287:9952–9961PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Vered M, Dayan D, Yahalom R et al. Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma. Int J Cancer 127:1356–1362Google Scholar
  30. 30.
    Ito Y, Yoshida H, Nakano K et al (2003) Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. Histopathology 43:157–164PubMedCrossRefGoogle Scholar
  31. 31.
    Maeda T, Desouky J, Friedl A (2006) Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25:1408–1412PubMedCrossRefGoogle Scholar
  32. 32.
    Gotte M, Kersting C, Ruggiero M et al (2006) Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 26:621–627PubMedGoogle Scholar
  33. 33.
    Roh YH, Kim YH, Choi HJ et al (2009) Fascin overexpression correlates with positive thrombospondin-1 and syndecan-1 expressions and a more aggressive clinical course in patients with gallbladder cancer. J Hepatobiliary Pancreat Surg 16:315–321PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2013

Authors and Affiliations

  • Sung Hak Lee
    • 1
  • Eun Ji Choi
    • 2
  • Min Sik Kim
    • 3
  • Jun Wook Park
    • 3
  • Youn Soo Lee
    • 1
  • Su Young Kim
    • 2
  • Chang Suk Kang
    • 1
  1. 1.Department of Hospital Pathology, College of MedicineThe Catholic University of KoreaSeoulKorea
  2. 2.Department of Pathology, College of MedicineThe Catholic University of KoreaSeoulKorea
  3. 3.Department of Otorhinolaryngology, College of MedicineThe Catholic University of KoreaSeoulKorea

Personalised recommendations